Figure 8.
The causal networks of downregulated osimertinib intervention and activated MNK1/2, which were predicted to be significant under L858R mutation status, illustrated together with the related inhibitors: dacomitinib and tomivosertib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.